Research analyst, medium-term horizon, biotech, small-cap

Check-Up On Avita Medical Keeps Us Bullish

Quick Financials Update

On August 29, 2013, Avita Medical Ltd (OTCQX:AVMXY) reported financial results for the six months and full year ended June 30, 2013. Total revenues for the six months ended June 30, 2013 were $2.18 million, up 13% over the same period in 2012. Revenues were driven by $1.46 million in product sales, consisting of sales of the ReCell® Spray-On Skin product in Europe and sales of the Breath-A-Tech® spacer and Funhaler® children's inhaler in Australia, and $0.72 million in grants relating to the U.S. Department of Defense and other income. For the full year 2013, revenues totaled $4.05 million, consisting of $2.82 million in product sales from ReCell, Breath-A-Tech, and Funhaler, and $1.24 million in...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details